Sopharma AD-Sofia (WAR:SPH) Interest Expense: zł-50 Mil (TTM As of Mar. 2026)


WAR:SPH Sopharma AD-Sofia WAR:SPH
66 GF Score
Price zł7.94
GF Value zł13.48
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sopharma AD-Sofia Interest Expense?

Sopharma AD-Sofia WAR:SPH +0.25% 66 Interest Expense is zł-50 Mil as of Mar. 2026. GuruFocus rates WAR:SPH with a GF Score™ of 66/100 and a GF Value™ of zł13.48 (Possible Value Trap). The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sopharma AD-Sofia's interest expense for the three months ended in Mar. 2026 was zł -11 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was zł-50 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sopharma AD-Sofia's Operating Income for the three months ended in Mar. 2026 was zł 143 Mil. Sopharma AD-Sofia's Interest Expense for the three months ended in Mar. 2026 was zł -11 Mil. Sopharma AD-Sofia's Interest Coverage for the quarter that ended in Mar. 2026 was 12.80. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sopharma AD-Sofia  (WAR:SPH) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sopharma AD-Sofia's Interest Expense for the three months ended in Mar. 2026 was zł-11 Mil. Its Operating Income for the three months ended in Mar. 2026 was zł143 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was zł475 Mil.

Sopharma AD-Sofia's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*142.813/-11.153
=12.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Sopharma AD-Sofia Interest Expense Historical Data

* Premium members only.

The historical data trend for Sopharma AD-Sofia's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma AD-Sofia Interest Expense Chart

Sopharma AD-Sofia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -23.41 -12.49 -23.28 -29.06 -49.09

Sopharma AD-Sofia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.75 -11.85 -12.87 -13.66 -11.15
WAR:SPH
66GF Score
Sopharma AD-Sofia WAR:SPH
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma AD-Sofia Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of zł-50 Mil mean?
Sopharma AD-Sofia (WAR:SPH) has a Interest Expense of zł-50 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sopharma AD-Sofia and its competitors.
Is Sopharma AD-Sofia's Interest Expense too high?
Sopharma AD-Sofia's current Interest Expense is zł-50 Mil. Overall, Sopharma AD-Sofia has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Interest Expense compare to MCK and CAH?
Sopharma AD-Sofia's Interest Expense of zł-50 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Distribution company?
A good Interest Expense depends on the Medical Distribution industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Interest Expense is zł-50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.48, compared to a current price of zł7.94 — trading 41.1% below its estimated fair value. The current Interest Expense is zł-50 Mil. Sopharma AD-Sofia's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Interest Expense is zł-50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued. The current stock price of zł7.94 is trading 41.1% below its estimated GF Value™ of zł13.48. GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.

Key valuation signals for WAR:SPH:

  • Interest Expense: zł-50 Mil
  • GF Value™: zł13.48 vs. price of zł7.94 (41.1% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma AD-Sofia Business Description

Other Exchanges 3JR:GermanySFA:Bulgaria
Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
66GF Score

Get the complete analysis for WAR:SPH

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.94
Price
zł13.48
GF Value